This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, K. V.
Right arrow Articles by Murray, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, K. V.
Right arrow Articles by Murray, B. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3640-3643, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3640-3643.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of a New Ketolide, ABT-773, against Multidrug-Resistant Gram-Positive Cocci

Kavindra V. Singh,1,2,* Kumthorn Malathum,1,2,dagger and Barbara E. Murray1,2,3

Center for the Study of Emerging and Re-emerging Pathogens,1 Division of Infectious Diseases, Department of Internal Medicine,2 and Department of Microbiology and Molecular Genetics,3 The University of Texas Medical School, Houston, Texas 77030

Received 1 February 2001/Returned for modification 14 August 2001/Accepted 18 September 2001

The in vitro activities of ABT-773 were evaluated against 324 strains of gram-positive bacteria, including multidrug-resistant Staphylococcus spp. and Enterococcus spp. ABT-773 had lower MIC ranges, MICs at which 50% of isolates are inhibited (MIC50s), and MIC90s than erythromycin or clindamycin for almost all isolates tested. The MICs of ABT-773 were also lower than those of quinupristin-dalfopristin (Q-D) for methicillin-susceptible Staphylococcus aureus, Rhodococcus spp., and Streptococcus spp., while the MICs of Q-D were lower than those of ABT-773 for methicillin-resistant S. aureus and Enterococcus faecium, including vancomycin-resistant isolates.

* Corresponding author. Mailing address: Center for the Study of Emerging and Re-emerging Pathogens, University of Texas Medical School-Houston, 6431 Fannin, 1.728 JFB, Houston, TX 77030. Phone: (713) 500-6758. Fax: (713) 500-5495. E-mail: Kavindra.Singh{at}uth.tmc.edu.

dagger Present address: Division of Infectious Diseases, Department of Internal Medicine, Ramathibodi Hospital, Rajjatheve, Bangkok, Thailand.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3640-3643, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3640-3643.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pai, S. R., Singh, K. V., Murray, B. E. (2003). In Vivo Efficacy of the Ketolide ABT-773 (Cethromycin) against Enterococci in a Mouse Peritonitis Model. Antimicrob. Agents Chemother. 47: 2706-2709 [Abstract] [Full Text]  
  • Hamilton-Miller, J. M. T., Shah, S. (2002). Activity of ketolide ABT-773 (cethromycin) against erythromycin-resistant Streptococcus pneumoniae: correlation with extended MLSK phenotypes. J Antimicrob Chemother 50: 907-913 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»